

EXPLANATORY STATEMENT
NATIONAL HEALTH ACT 1953
NATIONAL HEALTH (EFFICIENT FUNDING OF CHEMOTHERAPY) SPECIAL
ARRANGEMENT AMENDMENT INSTRUMENT 2012 (No. 6)

PB 48 of 2012

Authority

Subsection 100(1) of the *National Health Act 1953* (the Act) enables the Minister to make special arrangements for the supply of pharmaceutical benefits. Subsection 100(2) of the Act provides that the Minister may vary or revoke a special arrangement made under subsection 100(1).

Subsection 100(3) of the Act provides that Part VII of the Act, and instruments made for the purposes of Part VII have effect subject to a special arrangement made under subsection 100(1).

Purpose

The purpose of this legislative instrument, made under subsections 100(1) and 100(2) of the Act, is to amend the *National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011* (PB 79 of 2011) (the Special Arrangement), to make changes to the special arrangement relating to the efficient funding of chemotherapy.

The Special Arrangement achieves greater efficiency in payment for the supply of injected or infused chemotherapy medicines (“chemotherapy pharmaceutical benefits”) to eligible patients being treated for cancer, to reflect the 2010 budget measure titled ‘Revised arrangements for the efficient funding of chemotherapy drugs’. This Special Arrangement also relates to the supply of medicines associated with the side-effects of cancer and cancer treatment (“related pharmaceutical benefits”) at certain public hospitals.

This instrument makes changes to the pharmaceutical benefits available under the section 100 special arrangement for the efficient funding of chemotherapy. These changes reflect changes to the *National Health (Listing of Pharmaceutical Benefits) Instrument 2010* (the main listing instrument) made under sections 84AF, 85, 85A, 88 and 101 of the Act, which commence on the same day.

This Instrument:

- adds a pharmaceutical benefit containing the new listed drug ‘Cabazitaxel’;
- amends the circumstances for pharmaceutical benefits with the listed drug ‘Docetaxel’;
and
- adds 1 new listed brand with the listed drug ‘Topotecan’.

This Instrument also amends the definition of ‘participating hospital authority’ and inserts a definition for ‘National Health Reform Agreement’. This amendment reflects amendments to the *Federal Financial Relations Act 2009* that commenced 25 June 2012. The *Federal Financial Relations Act 2009* refers to the National Health Reform Agreement as agreed to by the Council of Australian Governments on 2 August 2011 as amended from time to time. A copy of the National Health Reform Agreement can be obtained at the Council of Australian Governments (“COAG”) website at <http://www.coag.gov.au>.

Consultations

An ongoing and formal process of consultation in relation to matters relevant to this instrument includes the involvement of interested parties through the membership of the Pharmaceutical Benefits Advisory Committee (PBAC). PBAC is an independent expert body established by section 100A of the Act which makes recommendations to the Minister about which drugs and medicinal preparations should be available as pharmaceutical benefits.

PBAC members are appointed following nomination by prescribed organisations and associations from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions. Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of PBAC, and that would enable them to contribute meaningfully to the deliberations of PBAC. When recommending the listing of a medicine on the Pharmaceutical Benefits Scheme (PBS), PBAC takes into account the medical conditions for which the medicine has been approved for use in Australia, its clinical effectiveness, safety and cost-effectiveness compared with other treatments.

This Instrument commences on 1 August 2012.

This Instrument is a legislative instrument for the purposes of the *Legislative Instruments Act 2003*.

A provision by provision description of this Instrument is contained in the [Attachment](#).

ATTACHMENT

PROVISION BY PROVISION DESCRIPTION OF THE NATIONAL HEALTH (EFFICIENT FUNDING OF CHEMOTHERAPY) SPECIAL ARRANGEMENT AMENDMENT INSTRUMENT 2012 (No. 6)

Section 1 Name of Instrument

This section provides that this Instrument is the *National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 6)* and that it may also be cited as PB 48 of 2012.

Section 2 Commencement

This section provides that this Instrument commences on 1 August 2012.

Section 3 Amendments to PB 79 of 2011

This section provides that Schedule 1 amends the *National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011* (PB 79 of 2011) (the Special Arrangement).

Schedule 1

Item 1 inserts a definition for ‘National Health Reform Agreement’ into section 3 of the Special Arrangement.

Item 2 amends the definition of ‘participating hospital authority’ in section 3 of the Special Arrangement by replacing the reference to the National Healthcare Agreement with a reference to the National Health Reform Agreement.

Item 3 inserts a new listed drug ‘Cabazitaxel’ into Schedule 1 Part 1 of the Special Arrangement by adding a new pharmaceutical benefit, which is the listed drug ‘Cabazitaxel’ in the form ‘Concentrated injection 60mg (as acetone solvate) in 1.5 mL, with diluent’ with the manner of administration ‘Injection’ and brand ‘Jevtana’.

Item 4 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL with solvent’ with the manner of administration ‘Injection’ and brand ‘Taxotere’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 5 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL with solvent’ with the manner of administration ‘Injection’ and brand ‘Taxotere’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 6 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Powder for I.V. infusion 20 mg with solvent’ with manner of administration ‘Injection’ and brand ‘Docetaxel SUN’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 7 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Powder for I.V. infusion 80 mg with solvent’ with manner of administration ‘Injection’ and brand ‘Docetaxel SUN’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 8 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 140 mg in 7 mL’ with manner of administration ‘Injection’ and brand ‘Oncotaxel 140’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 9 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 160 mg in 16 mL’ with manner of administration ‘Injection’ and brand ‘DBL Docetaxel Concentrated Injection’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 10 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 20 mg in 1 mL’ with manner of administration ‘Injection’ and brand ‘Oncotaxel 20’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 11 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 20 mg in 1 mL with manner of administration ‘Injection’ and brand ‘Taxotere’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 12 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 20 mg in 2 mL with manner of administration ‘Injection’ and brand ‘DBL Docetaxel Concentrated Injection’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 13 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 20 mg in 2 mL’ with manner of administration ‘Injection’ and brand ‘Docetaxel Ebewe’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 14 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 20 mg in 2 mL’ with manner of administration ‘Injection’ and brand ‘Docetaxel Sandoz’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 15 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 80 mg in 4 mL’ with manner of administration ‘Injection’ and brand ‘Oncotaxel 80’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 16 amends the entry in Schedule 1 Part 1 for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 80 mg in 4 mL’ with manner of administration ‘Injection’ and brand ‘Taxotere’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 17 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 80 mg in 8 mL’ with manner of administration ‘Injection’ and brand ‘DBL Docetaxel Concentrated Injection’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 18 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 80 mg in 8 mL’ with manner of administration ‘Injection’ and brand ‘Docetaxel Ebewe’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 19 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 80 mg in 8 mL’ with manner of administration ‘Injection’ and brand ‘Docetaxel Sandoz’ by removing the circumstances code ‘C3884’ and adding the circumstances code ‘C7002’.

Item 20 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Topotecan’ by adding a new pharmaceutical benefit, which is the listed drug ‘Topotecan’ in the form ‘Powder for I.V. infusion 4 mg (as hydrochloride)’ with manner of administration ‘Injection’ and brand ‘Topotecan Kabi’.

Item 21 amends Schedule 1 Part 2 of the Special Arrangement by adding the maximum amount and number of repeats for the new listed drug ‘Cabazitaxel’.

Item 22 amends Schedule 4 of the Special Arrangement by adding circumstances codes and associated circumstances for the new listed drug ‘Cabazitaxel’.

Item 23 amends the entry in Schedule 4 of the Special Arrangement for ‘Docetaxel’ by removing circumstances code ‘C3884’ and the circumstances associated with it and inserting circumstances code ‘C7002’ and the circumstances associated with it.

Statement of Compatibility with Human Rights

Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 6)

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*.

Overview of the Legislative Instrument

The purpose of this legislative instrument, made under subsections 100(1) and 100(2) of the Act, is to amend the *National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011* (PB 79 of 2011) (the Special Arrangement), to make changes to the special arrangement relating to the efficient funding of chemotherapy.

The Special Arrangement achieves greater efficiency in payment for the supply of injected or infused chemotherapy medicines (“chemotherapy pharmaceutical benefits”) to eligible patients being treated for cancer, to reflect the 2010 budget measure titled ‘Revised arrangements for the efficient funding of chemotherapy drugs’. This Special Arrangement also relates to the supply of medicines associated with the side-effects of cancer and cancer treatment (“related pharmaceutical benefits”) at certain public hospitals.

This Instrument:

- adds a pharmaceutical benefit containing the new listed drug ‘Cabazitaxel’;
- amends the circumstances for pharmaceutical benefits with the listed drug ‘Docetaxel’;
- adds 1 new listed brand with the listed drug ‘Topotecan’; and
- amends the definition of ‘participating hospital authority’ and inserts a definition for ‘National Health Reform Agreement’.

Human rights implications

This legislative instrument engages Article 2 and 12 of the International Covenant on Economic, Social and Cultural Rights (ICESCR) by assisting with the progressive realisation by all appropriate means of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.

The Pharmaceutical Benefits Scheme (PBS) is a benefit scheme which assists with advancement of this human right by providing for subsidised access by patients to medicines. The recommendatory role of the Pharmaceutical Benefits Advisory Committee (PBAC) ensures that decisions about subsidised access to medicines on the PBS are evidence-based.

Conclusion

This Legislative Instrument is compatible with human rights because it advances the protection of human rights.

**Felicity McNeill
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing**